Abogen is pleased to announce the appointment of Dr. Weimin Li as President of Preclinical Research. In this role, Dr. Li will oversee the company’s preclinical R&D strategy and pipeline planning, accelerate the clinical translation of pipeline programs, and further advance global innovations in RNA-based therapeutics.

With more than 20 years of experience in the biopharmaceutical industry, Dr. Li brings a global strategic perspective and strong R&D management capability. He has held senior leadership roles at leading global biopharmaceutical companies, including Johnson & Johnson, AstraZeneca, and Takeda Pharmaceuticals, with expertise spanning drug discovery, translational medicine, and early clinical development.

Dr. Li possesses a proven track record across oncology, immunology, cell therapy and other emerging therapeutic modalities. He has played an instrumental role in advancing innovative drug programs from early-stage development and contributing to NDA and BLA approvals for drugs such as Zytiga, Erleada, Imfinzi, and Imjudo.

“We are delighted to welcome Dr. Weimin Li to Abogen,” said Dr. Bo Ying, Founder, Chairman, and CEO of Abogen. “Dr. Li’s exceptional R&D leadership and extensive experience in innovative drug development strongly aligns with our strategic goals. We believe his expertise will further strengthen our ability to translate RNA innovation through preclinical R&D, and help navigate Abogen through our next phase of growth.”

“I am impressed with Abogen’s proprietary, end-to-end technology platform, and the steady stream of R&D milestones that reflect the company’s robust innovation vitality,” said Dr. Weimin Li, “I’m looking forward to collaborating with this excellent team to advance our preclinical research, accelerate translational medicine, and reinforce Abogen’s leadership at the forefront of RNA innovation. Together, we strive to transform cutting-edge technology into safer, more effective clinical solutions.”